19 results about "Mesenchyme" patented technology

The application relates to an IL-10 high-expression mesenchymal stem cell secretion component, a preparation method thereof and application thereof in prevention and treatment of ischemic cerebral stroke, and belongs to the technical field of cerebral stroke treatment. In order to solve the problems existing in the current stem cell clinical medication and administration method for ischemic cerebral stroke, the application provides a specially treated mesenchymal stem cell secretion component (hMSC-M), the secretion component is an IL-10 high-expression stem cell secretion component obtained by using a basic culture medium containing human IFN-gamma protein and TNF-alpha simulation peptide to induce human mesenchymal cells after expansion, and then harvesting culture and repeatedly freezing and thawing. The application finds that the hMSC-M has a significant effect on prevention and treatment of ischemic cerebral stroke through animal experiments, thereby opening up a new drug use for stem cell application, laying a foundation for developing high-efficiency related drugs for preventing and treating ischemic cerebral stroke injury, and providing a new application scheme and thought.

A method of promoting return to estrus in an animal and an agent for promoting return to estrus in an animal are provided. The method is a method of promoting return to estrus in an animal, characterized by including a step of administering mesenchymal stromal cells or a composition containing mesenchymal stromal cells to the animal. The mesenchymal stromal cells are preferably adipose-derived stem cells, and the animal is preferably a farm animal, a dog, or a cat.

In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and / or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.

The invention discloses a large-scale stem cell culture method, and relates to the technical field of stem cell culture, and the method comprises the following steps: stem cell pretreatment: taking P3-P5 generation mesenchymal or embryo dry and thin parts, digesting for 2-3 minutes at 37 + / -0.5 DEG C by using trypsin containing 0.01%-0.05% of EDTA (Ethylene Diamine Tetraacetic Acid), the pretreated cells are inoculated to a bioreactor containing a modified microcarrier, the microcarrier is a chitosan and gelatin composite material, the aperture is 50-100 microns, the particle size is 200-300 microns, RGD peptide is grafted, dynamic fed-batch culture is conducted, the concentration of glucose and lactic acid is detected in real time through an intelligent feedback system, harvesting and purification are conducted, 0.02%-0.04% of collagenase is added after culture is finished, incubation is conducted for 15-20 min at the temperature of 37 DEG C, and the concentration of glucose and lactic acid in the bioreactor is detected. The limitation of a traditional single-material microcarrier is broken through, the chitosan and gelatin composite carrier is adopted, RGD peptide is grafted, the cell attachment rate is increased, a three-dimensional growth space is provided for cells through specific aperture / particle size design, and the problem of poor cell uniformity in large-scale culture is solved.

The present invention pertains to an improved mesenchymal stromal cell (MSC) preparation and a method for producing the same. The invention provides a new strategy to isolate MSC from bone marrow mononuclear cells (BM-MNCs) by pooling BM-MNCs of multiple unrelated (third-party) bone marrow donors. The MSC preparation manufactured in accordance with the methodology of the invention is characterized by a stable proliferative capability and an increased immunosuppressive potential when compared to individual donor MSC preparations or a pool of individual MSCs generated from multiple donors. The MSCs prepared according to the invention are particularly useful for medical applications such as the treatment of graft-versus-host disease (GvHD) in recipients with hematopoietic stem cell transplants, patients with autoimmune disorders and as a cell-based therapy in regenerative medicine.

The present invention relates to the technical field of cell therapy. Specifically disclosed are a mesenchymal stromal cell-based drug and a use thereof in the treatment of acute cerebral infarction. The present invention provides a cell-based drug, comprising mesenchymal stromal cells and a pharmaceutically acceptable excipient. Compared with stem cells, the mesenchymal stromal cells have a negative expression level of mRNA encoding self-renewal and differentiation in the mesenchymal stromal cells. The mesenchymal stromal cells account for 90% or more of the cell-based drug. The cell-based drug exhibits the characteristics and mechanism of action of stromal cells, homes to the neovasculature formed by endothelial cells at the injury site within an effective time window, plays a role in promoting / maintaining the neovasculature and remodeling the microenvironment of the injury site, fully ensures the safety and effectiveness of disease treatment, and provides a novel method for the diagnosis and treatment of related diseases.

The application provides a nucleic acid molecule, a pro-angiogenic mesenchymal stromal cell and application thereof, relates to the biomedical technical field, and the nucleic acid molecule encodes HGF protein, or encodes VEGF165 protein and HGF protein; a first signal peptide is used as the signal peptide of the VEGF165 protein, and a second signal peptide is used as the signal peptide of the HGF protein. Through a gene modification strategy, MSC cells containing the nucleic acid molecule can stably and efficiently express VEGF165 and / or HGF, and the expression amount is significantly higher than that of MSC without the nucleic acid molecule. The cells have the ability to promote the migration of endothelial cells; meanwhile, the cells can also significantly promote the proliferation and tube formation of HUVEC cells, and further confirm the strong pro-angiogenic effect. The technical problem that nucleic acid molecules expressing VEGF165 or / HGF cannot be stably and efficiently expressed in the prior art is solved.

Compositions and methods of transplanting cells by grafting strategies into solid organs (especially internal organs) are provided. These methods and compositions can be used to repair diseased organs or to establish models of disease states in experimental hosts. The method involves attachment onto the surface of a tissue or organ, a patch graft, a “bandaid-like” covering, containing epithelial cells with supporting early lineage stage mesenchymal cells. The cells are incorporated into soft gel-forming biomaterials prepared under serum-free, defined conditions comprised of nutrients, lipids, vitamins, and regulatory signals that collectively support stemness of the donor cells. The graft is covered with a biodegradable, biocompatible, bioresorbable backing used to affix the graft to the target site. The cells in the graft migrate into and throughout the tissue such that within a couple of weeks they are uniformly dispersed within the recipient (host) tissue. The mechanisms by which engraftment and integration of donor cells into the organ or tissue involve multiple membrane-associated and secreted forms of MMPs.

Provided herein are novel compositions comprising Human Mesenchymal Conditioned Media from mammalian-derived, such as human-derived, cell sources, wherein the cell sources comprise bone marrow mesenchymal cells (BM-MSCs), umbilical cord mesenchymal cells (UC-MSCs), and fibroblast cells. The compositions may be used for formulations and skincare solutions suitable for use for cosmeceutical applications.

The invention relates to a method for producing a mesenchymal stem cell (MSC), the method comprising culturing a primitive mesoderm cell in a mesenchymal colony forming medium (M-CFM) comprising LiCl and FGF2, but excluding PDGF, under normoxic conditions for sufficient time for a mesenchymal colony to form, and culturing the mesenchymal colony adherently to produce the MSC, wherein the MSC has superior T-cell immunosuppressive properties relative to an MSC not produced in said M-CFM. The invention also relates to an MSC produced by the method, a population of MSCs produced by the method, a therapeutic composition comprising the MSC produced by the method, an M-CFM and an M-CFM in concentrated form, and method and uses of the MSC or population in treating a disease.

The invention relates to a method for producing mesenchymal stem cells with bone differentiation tendency by using extraembryonic mesoderm cells. Specifically, the invention develops a method for inducing and differentiating human pluripotent stem cells into embryonic ectomesoderm cells in vitro, and optimizes induction culture conditions and a purification method. The obtained extraembryonic mesoderm cells are further subjected to differentiation culture, so that the mesenchymal stem cells can be stably obtained, and the obtained mesenchymal stem cells have a bone differentiation tendency and lack the capability of differentiating to adipocytes. The mesenchymal cells obtained through in-vitro culture have application prospects in the field of cell therapy of bone related diseases.

The present disclosure relates to a genetically modified stem cells (e.g., mesenchymal stromal cells (MSCs) or pluripotent stem cells (PSCs)) and populations thereof, that comprise an exogenous nucleic acid that encodes a binding protein that binds to a target. Targets include, for example, proteins expressed on activated immune cells. Binding proteins expressed by genetically modified stem cells as described herein can include one or more binding domains from an antibody or antibody mimetic. Also provided are methods of making genetically modified stem cells, pharmaceutical preparations including genetically modified stem cells, and methods of using the same, for example, in the treatment of immune diseases, including inflammatory, autoimmunity and cancer.

The invention belongs to the technical field of cell biology, and particularly relates to an anti-aging mesenchymal stromal cell as well as a construction method and application thereof. The construction method of the anti-aging mesenchymal stromal cells comprises the following steps: S1, culturing in vitro and carrying out passage on the mesenchymal stromal cells to P5 to P10 generations; s2, placing the mesenchymal stromal cells in a microgravity environment for rotary culture; and S3, digesting the cultured cells to obtain the anti-aging mesenchymal stromal cells. Compared with the prior art of simulating microgravity to explore phenotypes such as morphology, proliferation, immunity and the like of the mesenchymal stromal cells, a new breakthrough is made, and a new strategy and thought are provided for delaying stromal cell senescence, researching mechanisms of space weightlessness related diseases and increasing clinical application of stromal cells.

The invention discloses a method for inducing and converting mesenchymal cells into neural stem cells, which relates to the technical field of biology and comprises the following steps: (a) providing a group of mesenchymal stem cells cultured in vitro; (b) culturing the mesenchymal stem cells in an induction medium, and inducing the mesenchymal stem cells to differentiate into neural stem cells; wherein the induction medium comprises a basal medium and the following components in effective induction concentrations: a histone deacetylase inhibitor (HDAC inhibitor); a glycogen synthase kinase-3beta inhibitor (GSK-3beta inhibitor); a retinoic acid receptor agonist; the invention provides a set of technical scheme for inducing and transforming the mesenchymal stem cells into the neural stem cells for the first time, which is clear in components, efficient, stable, high in universality and simple and convenient to operate, not only fills the blank in the prior art, but also provides a new cell source and technical support for medical research and clinical treatment of nerve regeneration. The method has an important scientific research value and a wide application prospect.

Provided herein is a method for controlling a rate of fatty acid oxidation in mesenchymal cells, comprising modulating the expression or activity of ADCY5. The rate of fatty acid oxidation may be decreased by reducing the expression or activity of ADCY5. The rate of fatty acid oxidation may be increased by increasing the expression or activity of ADCY5. In some embodiments, the mesenchymal cell may be a mesenchymal stem cell, an adipocyte, an osteoblast, a chondrocyte, or a myocyte. In some embodiments, controlling the rate of fatty acid oxidation in mesenchymal stem cells comprises inhibiting fatty acid oxidation. In some embodiments, inhibiting fatty acid oxidation prevents development of Type 2 Diabetes (T2D). In some embodiments, controlling the rate of fatty acid oxidation in mesenchymal stem cells may comprise increasing the rate of fatty acid oxidation. Increasing the rate of fatty acid oxidation may promote bone formation.

Provided herein are novel compositions comprising Human Mesenchymal Conditioned Media from mammalian-derived, such as human-derived, cell sources, wherein the cell sources comprise bone marrow mesenchymal cells (BM-MSCs), umbilical cord mesenchymal cells (UC-MSCs), and fibroblast cells. The compositions may be used for formulations and skincare solutions suitable for use for cosmeceutical applications.

Methods of stimulating production of specialized pro-resolving mediators (SPMs) by mesenchymal stem cells (MSCs) are provided. The methods include contacting MSCs with one or more SPM fatty acid precursors, SPM intermediates, or a combination of two or more thereof. Also provided are compositions including the stimulated MSCs or conditioned media from the stimulated MSCs. Methods of treating or inhibiting inflammation are also provided, including administering to a subject stimulated MSCs or conditioned media from stimulated MSCs.

The invention is suitable for the technical field of bioengineering, and provides a cornu cervi pantotrichum stem cell exosome and application thereof.The method comprises the following steps that a 3 cm section of the top end of a cornu cervi pantotrichum in the growth stage is cut out, mesenchymal layer tissue is collected and cut into tissue blocks for primary cornu cervi pantotrichum mesenchymal stem cell RMCs culture, cells are cultured through an alpha-MEM culture medium, and the cornu cervi pantotrichum stem cell exosome is obtained; purifying the primary cells through a limited dilution method to obtain stem cells; the method comprises the following steps: preparing exosome-free serum through a gradient centrifugation method in advance; and after 80% of the RMCs are fused, replacing the culture medium with an alpha-MEM complete culture medium containing 10% of the exosome-free serum, performing culture, collecting supernate, performing centrifugal operation, collecting precipitates, and performing PBS resuspension to obtain the exosome RMC-Exos. Another purpose of the embodiment of the invention is to provide the cornu cervi pantotrichum stem cell exosome which is prepared by adopting the preparation method. According to the invention, it is clear that RMC-Exos can be used as a biological material, a regeneration promoting microenvironment can be recovered, and a new way with a prospect is provided for periodontal regeneration.

A dura mater-derived stem cell and a method of producing the same according to the present invention establish a method of isolating and producing stem cells from the dura mater by adding serum or a serum substitute, which is a culture supplement, to a conventionally used medium. The dura mater-derived stem cells produced by the production method of the present invention were confirmed to have excellent differentiation potency into mesenchymal and neurons and exhibit physical characteristics that enable them to maintain high cell viability when transplanted into cell therapeutic agents. Furthermore, they have been confirmed to possess inherent expression marker characteristics so that they can be effectively used in various applications including cell therapeutic agents.